Sentencing for FD&C Act violations
Executive Summary
The U.S. Sentencing Commission is considering amending sentencing guidelines applied to individuals and organizations convicted of criminal FD&C Act violations, and FDA's Office of Criminal Investigations appears to be pushing for stronger guidelines, according to Hyman, Phelps & McNamara's FDA law blog. The Commission's proposed priorities include treatment under the guidelines of offenses related to human growth hormone (of which there are currently none) and the Prescription Drug Marketing Act (for which the statutory maximum is 10 years). The commission has until May 1, 2008, to submit guideline amendments to Congress...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.